 |
|
|
| |
Satisfaction, Tolerability, and Acceptability of Cabotegravir (CAB) + Rilpivirine (RPV) Long-Acting Therapy: LATTE-2 Results
|
| |
| |
Reported by Jules Levin
Durban IAC 2016 July 18-22
Miranda Murray,1 David Dorey,2 Sandy Griffith,3 Joseph Mrus,4 William Spreen,3 David Margolis3
1ViiV Healthcare, London, UK; 2GlaxoSmithKline, Mississauga, Ontario, Canada; 3ViiV Healthcare, Research Triangle Park, NC, USA; 4Janssen Research & Development, Raritan, NJ, USA
|
| |
|
|
|
|
|
